Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients - Takeaways - MDSpire

Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients

Jacqueline Garcia, MD, of Dana-Farber Cancer Institute presented at #ASH24 data suggesting oral maintenance therapy with venetoclax and decitabine/cedazuridine after HCT is safe, feasible, and may reduce relapse rates in high-risk AML/MDS patients.

  • January 9, 2025

Share

  • 1

    Oral maintenance therapy with venetoclax and decitabine/cedazuridine is safe and feasible for high-risk AML/MDS patients after HCT.

  • 2

    In a study of 30 patients, 87% were able to initiate planned maintenance therapy without significant complications.

  • 3

    The regimen showed tolerability with no grade 3 or 4 non-hematologic toxicities, though some expected hematologic toxicities occurred.

  • 4

    After 22 months, the study reported a 1-year overall survival rate of 81% and a progression-free survival rate of 73%.

  • 5

    The cumulative incidence of relapse at 1 year was 27%, indicating promising outcomes for high-risk patients undergoing transplantation.

Original Source(s)

Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients

  • January 9, 2025

Related Content

Surgical treatment of spondylodiscitis in critically ill septic patients

Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo

Microbiological and Clinical Features of Polymicrobial Bloodstream Infections in Patients with Hematologic Malignancies: A Cross-Sectional Analysis